MBNL1 and myotonic dystrophy type 1: Delivery of this modified MBNL1 decoy via an adeno-associated virus (AAV) into the skeletal muscle of a DM1 mouse model significantly ameliorated the disease phenotype, representing a promising approach for DM1 therapy.